• linkedin
  • Increase Font
  • Sharebar

    Research offers insights on clinical course, management of CSCR

    Acute central serous chorioretinopathy (CSCR) resolves within six months in the majority of patients, but findings from new research suggests ways to identify individuals at risk for longer duration and a new approach to treating patients with severe chronic CSCR with epitheliopathy.

    Dr. Behar-Cohen

    “Only a subset of patients with CSCR will have a long episode,” said Francine Behar-Cohen, MD, professor of ophthalmology, University of Paris Descartes and Cochin Hospital, both of Paris, France. “These patients are the ones who need to be identified for treatment and when evaluating therapy. In addition, it is important to be able to identify individuals at risk for recurrence because recurrence leads to long-term visual impairment.”

    To identify factors predicting a longer episode duration, Dr. Behar-Cohen and colleagues analyzed data from 31 consecutive patients with a first episode of acute CSCR and symptom duration <20 days. The patients had a mean age of 40 years and 84% were male.

    Mean time to resolution was 83 days, and CSCR resolved by 6 months in 26 (84%) eyes. By 3 months, however, 52% of the cases had resolved.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';